Fundraising FoxAttralus
South San Francisco, US · Founded 2019 · Delaware corporation · 14 known investors
Find your way into Attralus
Sign up to see every warm intro you have to Attralus
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Attralus team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages. The company operates in the biotech and drug development space targeting these progressive, often fatal diseases.
Founders & leadership
Attralus was founded in 2019 by Jonathan Wall.
JW
Jonathan WallFounder · Manager, CMC Data and Document Management2021–2022Jonathan Wall brings over a decade of experience in FDA-regulated biotechnology, with expertise in quality management systems, cGMP compliance, and cross-functional program management across manufacturing, engineering, and regulatory functions. He has led complex validation and remediation initiatives while coordinating between quality, operations, and compliance teams.
SG
Spencer GuthrieExecutive
MT
Mark TimneyCEO & Board Member, Attralus TherapeuticsMark Timney is an executive with extensive biopharmaceutical industry experience, having held senior operational and commercial leadership roles across multiple companies in the U.S., Japan, South Korea, U.K., Australia, and New Zealand, where he oversaw acquisitions, divestitures, business operations, drug launches, and pipeline governance.
BF
Benson FongNamed on SEC filing
GB
Greg BellNamed on SEC filing
JB
Jake BauerNamed on SEC filing
Board
AD
Alex DennerBoard director
RG
CG
NM
Nancy Miller-RichBoard director
Investors · 14
Alpha Wave Globallisted by Alpha Wave GlobalMiami
How we know: Alpha Wave Global's portfolio page · Not right? Tell us
LifeSci Venture Partnerslisted by LifeSci Venture PartnersNew York
How we know: LifeSci Venture Partners's portfolio page · Not right? Tell us
venBio Partnerslisted by venBio PartnersSan Franciscovia Corey Goodman · board
How we know: a partner's Signal profile · board seat on SEC Form D · funding news · prnewswire.com · the VCSheet dataset · Not right? Tell us
REDMILEreportedSan Francisco
How we know: globalgenes.org · Not right? Tell us
Also in the syndicate · 5
Alpha Wave VenturesleadBristol Myers SquibbLogos CapitalSarissa Capital ManagementSurveyor Capital (a Citadel company)
Funding
SEC filings, press & company announcements$197.8M disclosed across 4 rounds · 2019–2024
- $25MSeries ASep 2020 · 2 sources
venBio Partners (lead)
Source ↗
▶$56MraisedFeb 2024 · 12 investors · BiotechnologyRule 506(b)
▶$56MraisedFeb 2024 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark TimneyExecutive Officer, Director
- Richard GasterDirector
- Mehdi KhodadadExecutive Officer
- Corey GoodmanDirector
- Glen FirestoneExecutive Officer
- Rahul KakkarDirector
- Gregory BellExecutive Officer
- Spencer GuthrieExecutive Officer
- James TestaExecutive Officer
- Jake BauerDirector
- Nancy Miller-RichDirector
- Alex DennerDirector
- Offering amount
- $56M
- Amount sold
- $56M
- Minimum investment
- $24.4K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$116.6MraisedSep 2021 · 22 investors · BiotechnologyRule 506(b)
▶$116.6MraisedSep 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benson FongExecutive Officer
- Rahul KakkarDirector
- Greg BellExecutive Officer
- Jake BauerDirector
- Spencer GuthrieExecutive Officer
- Alex DennerDirector
- Richard GasterDirector
- Nancy Miller-RichDirector
- Mark TimneyExecutive Officer, Director
- Corey GoodmanDirector
- Jonathan WallExecutive Officer
- Offering amount
- $116.6M
- Amount sold
- $116.6M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$175KraisedDec 2019 · 5 investors · BiotechnologyRule 506(b)
▶$175KraisedDec 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan WallDirector
- Spencer GuthrieExecutive Officer, Director
- Amount sold
- $175K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
TrisaluslifesciTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
LatusLatus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise. The company operates from Philadelphia and Boston, serving the biotechnology and therapeutics industry.
Companies working in the same space as Attralus.
In the news
Frequently asked questions
- What does Attralus do?
- Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages. The company operates in the biotech and drug development space targeting these progressive, often fatal diseases.
- Who founded Attralus?
- Attralus was founded by Jonathan Wall in 2019.
- Who are Attralus's investors?
- Attralus's investors include Alpha Wave Global, BioBrit, LifeSci Venture Partners, venBio Partners, Janus Henderson Investors, REDMILE, Samsara BioCapital, venBio Global Strategic and 1 more.
- How much funding has Attralus raised?
- Attralus has disclosed $197.8M raised across 4 rounds.
- Where is Attralus headquartered?
- Attralus is headquartered in South San Francisco, US.